The biggest losers of the session on the Wall Street include Neos Therapeutics, Inc. (NASDAQ:NEOS), which fell -0.11 points or -6.11% to trade at $1.69 as last check. The stock closed last session at $1.8 and sets an active trading volume day with a reported 205831 contracts so far this session. NEOS shares had a relatively better volume day versus average trading capacity of 387.75 thousand shares, but with a 44.74 million float and a -15.49% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for NEOS stock indicates that the average analyst price target is $10.8 per share. This means the stock has a potential increase of 539.05% from where the NEOS share price has been trading recently which is between $1.76 and $1.86. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $4.
The shorts are running away from Neos Therapeutics, Inc. (NEOS) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a drop in short interest in NEOS shares. While short interest still represents only 5.71% of NEOS’s float, the number of shares shorted have fallen by -80669. The number of shares shorted fell to 2475484 shares, down from 2556153 shares during the preceding fortnight. With average daily trading volumes at 267442 shares, days to cover increased to about 6.997427 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Edited Transcript of NEOS earnings conference call or presentation 9-May-19 12:30pm GMT” and dated May 15, 2019.
During the recent trading session for Neos Therapeutics, Inc. (NASDAQ:NEOS), the company witnessed their stock drop by $-0.37 over a week and tumble down $-0.26 from the price 20 days ago. When compared to their established 52-week high of $7.75, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 05/21/18. The recent low of $1.4 stood for a -78.19% since 12/26/18, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0.97 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Neos Therapeutics, Inc., the two-week RSI stands at 25.18. This figure suggests that NEOS stock, for now, is overbought, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current NEOS readings is similarly very revealing as it has a stochastic reading of 4.19% at this stage. This figure means that NEOS share price today is being overbought.
Technical chart claims that Neos Therapeutics, Inc. (NEOS) would settle between $1.85/share to $1.91/share level. However, if the stock price goes below the $1.75 mark, then the market for Neos Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $1.71 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.19. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at RBC Capital Mkts lifted target price for shares of NEOS but were stick to Outperform recommendation for the stock in their opinion released on August 09. The price target has been raised from $20 to $12. Cantor Fitzgerald, analysts launched coverage of Neos Therapeutics, Inc. (NASDAQ:NEOS) stock with a Overweight recommendation, according to their flash note issued to investors on August 01. Analysts at UBS lowered the stock to a Neutral call from its previous Buy recommendation, in a research note that dated back to March 20.
NEOS equity has an average rating of 2, with the figure leaning towards a bullish end. 5 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 4 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 4 analysts rated Neos Therapeutics, Inc. (NASDAQ:NEOS) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, NEOS stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 1.66 while for the average stock in the same group, the multiple is 7.51.
Neos Therapeutics, Inc. (NEOS)’s current-quarter revenues are projected to climb by nearly 47.01% to hit $16.7 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 40.23% from $49.99 million to a noteworthy $70.1 million. At the other end of the current quarter income statement, Neos Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly 69.23% to hit $-0.16 per share. For the fiscal year, NEOS’s earnings are projected to climb by roughly 61.88% to hit $-0.61 per share.